OraSure Technologies (NASDAQ:OSUR) CFO Kenneth Mcgrath Buys 22,021 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath bought 22,021 shares of the stock in a transaction dated Friday, March 13th. The stock was purchased at an average price of $3.00 per share, with a total value of $66,063.00. Following the acquisition, the chief financial officer owned 557,262 shares of the company’s stock, valued at $1,671,786. The trade was a 4.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

OraSure Technologies Price Performance

OSUR opened at $3.13 on Tuesday. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $4.22. The firm has a market capitalization of $216.38 million, a P/E ratio of -3.37 and a beta of 0.88. The company’s 50-day moving average is $2.83 and its 200 day moving average is $2.79.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%. On average, equities research analysts expect that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Institutional Trading of OraSure Technologies

A number of large investors have recently added to or reduced their stakes in OSUR. Altai Capital Management L.P. raised its position in OraSure Technologies by 73.4% in the third quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock worth $12,034,000 after acquiring an additional 1,586,488 shares during the period. Private Management Group Inc. grew its position in shares of OraSure Technologies by 23.6% during the 2nd quarter. Private Management Group Inc. now owns 5,461,440 shares of the medical instruments supplier’s stock valued at $16,384,000 after acquiring an additional 1,044,213 shares during the period. Systematic Financial Management LP increased its stake in shares of OraSure Technologies by 35.3% during the 2nd quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier’s stock worth $6,687,000 after purchasing an additional 581,926 shares during the last quarter. Cannell Capital LLC raised its holdings in shares of OraSure Technologies by 12.6% in the 3rd quarter. Cannell Capital LLC now owns 2,099,815 shares of the medical instruments supplier’s stock worth $6,740,000 after purchasing an additional 234,826 shares during the period. Finally, Peapod Lane Capital LLC raised its holdings in shares of OraSure Technologies by 51.1% in the 4th quarter. Peapod Lane Capital LLC now owns 1,018,470 shares of the medical instruments supplier’s stock worth $2,465,000 after purchasing an additional 344,437 shares during the period. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, OraSure Technologies currently has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.